Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)

BACKGROUND: Immune checkpoint inhibitors (ICIs) are currently the standard of care for metastatic urothelial cancer (mUC) after the failure of previous platinum-based chemotherapy. The choice of further therapy after ICI progression is a new challenge, and scarce data support it. We aimed to examine...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Med Insights Oncol
Main Authors: Bersanelli, Melissa, Buti, Sebastiano, Cortellini, Alessio, Bandini, Marco, Banna, Giuseppe Luigi, Pederzoli, Filippo, Farè, Elena, Raggi, Daniele, Giannatempo, Patrizia, De Giorgi, Ugo, Basso, Umberto, Losanno, Tania, Santini, Daniele, Mucciarini, Claudia, Tucci, Marcello, Tambaro, Rosa, Farnesi, Azzurra, Caffo, Orazio, Veccia, Antonello, Naglieri, Emanuele, Briganti, Alberto, Procopio, Giuseppe, Pignata, Sandro, Necchi, Andrea
Format: Artigo
Sprog:Inglês
Udgivet: SAGE Publications 2021
Fag:
Original Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8274126/
https://ncbi.nlm.nih.gov/pubmed/34290538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/11795549211021667
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker